MX2019001153A - Peptidos ciclicos como antagonistas del receptor c5a. - Google Patents
Peptidos ciclicos como antagonistas del receptor c5a.Info
- Publication number
- MX2019001153A MX2019001153A MX2019001153A MX2019001153A MX2019001153A MX 2019001153 A MX2019001153 A MX 2019001153A MX 2019001153 A MX2019001153 A MX 2019001153A MX 2019001153 A MX2019001153 A MX 2019001153A MX 2019001153 A MX2019001153 A MX 2019001153A
- Authority
- MX
- Mexico
- Prior art keywords
- receptor antagonists
- cyclic peptides
- disorders
- processes
- formula
- Prior art date
Links
- 102000005590 Anaphylatoxin C5a Receptor Human genes 0.000 title abstract 3
- 108010059426 Anaphylatoxin C5a Receptor Proteins 0.000 title abstract 3
- 102000001189 Cyclic Peptides Human genes 0.000 title abstract 3
- 108010069514 Cyclic Peptides Proteins 0.000 title abstract 3
- 239000002464 receptor antagonist Substances 0.000 title abstract 3
- 229940044551 receptor antagonist Drugs 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invención se relaciona con derivados de péptidos cíclicos, con su uso en la medicina, con composiciones que los contienen, con procesos para su preparación y con productos intermediarios utilizados en tales procesos. Más en particular, la invención se relaciona con los antagonistas del receptor C5a del péptido cíclico de la fórmula (Ia) o de la fórmula (Ib), o con sales farmacéuticamente aceptables de los mismos, en donde las áreas R1a, R1b, R2, R3 y R4 se definen en la descripción. Los antagonistas del receptor C5a son potencialmente útiles en el tratamiento de un amplio margen de los trastornos 1, incluyendo trastornos inflamatorios y trastornos inmunes.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662368262P | 2016-07-29 | 2016-07-29 | |
| US201762517215P | 2017-06-09 | 2017-06-09 | |
| PCT/IB2017/054314 WO2018020358A1 (en) | 2016-07-29 | 2017-07-17 | Cyclic peptides as c5 a receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019001153A true MX2019001153A (es) | 2019-06-10 |
Family
ID=59416754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019001153A MX2019001153A (es) | 2016-07-29 | 2017-07-17 | Peptidos ciclicos como antagonistas del receptor c5a. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190270778A1 (es) |
| EP (1) | EP3491005A1 (es) |
| JP (1) | JP2019532021A (es) |
| KR (1) | KR20190032534A (es) |
| CN (1) | CN109563136A (es) |
| AU (1) | AU2017304103A1 (es) |
| BR (1) | BR112019001217A2 (es) |
| CA (1) | CA3031895A1 (es) |
| IL (1) | IL264537A (es) |
| MA (1) | MA45770A (es) |
| MX (1) | MX2019001153A (es) |
| SG (1) | SG11201811412XA (es) |
| WO (1) | WO2018020358A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3558363A1 (en) | 2016-12-21 | 2019-10-30 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| CN118490807A (zh) * | 2024-05-09 | 2024-08-16 | 无锡市第二人民医院 | 一种补体C5a在制备治疗眼科疾病药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| AUPO755097A0 (en) | 1997-06-25 | 1997-07-17 | University Of Queensland, The | Receptor agonist and antagonist |
| AUPR833401A0 (en) | 2001-10-17 | 2001-11-08 | University Of Queensland, The | G protein-coupled receptor antagonists |
| EP1498422A1 (de) | 2003-07-17 | 2005-01-19 | Jerini AG | C5a-Rezeptor-Antagonisten |
| EP1734981A4 (en) * | 2004-03-26 | 2010-03-10 | Promics Pty Ltd | TREATMENT OF NEUROLOGICAL CONDITIONS USING COMPLEMENT C5A RECEPTOR MODULATORS |
| SG158191A1 (en) * | 2005-01-17 | 2010-01-29 | Jerini Ag | C5a receptor antagonists |
-
2017
- 2017-07-17 MX MX2019001153A patent/MX2019001153A/es unknown
- 2017-07-17 JP JP2019504100A patent/JP2019532021A/ja active Pending
- 2017-07-17 EP EP17745516.9A patent/EP3491005A1/en not_active Withdrawn
- 2017-07-17 CN CN201780047049.4A patent/CN109563136A/zh active Pending
- 2017-07-17 US US16/319,985 patent/US20190270778A1/en not_active Abandoned
- 2017-07-17 SG SG11201811412XA patent/SG11201811412XA/en unknown
- 2017-07-17 CA CA3031895A patent/CA3031895A1/en not_active Abandoned
- 2017-07-17 KR KR1020197005513A patent/KR20190032534A/ko not_active Withdrawn
- 2017-07-17 BR BR112019001217-6A patent/BR112019001217A2/pt not_active IP Right Cessation
- 2017-07-17 WO PCT/IB2017/054314 patent/WO2018020358A1/en not_active Ceased
- 2017-07-17 MA MA045770A patent/MA45770A/fr unknown
- 2017-07-17 AU AU2017304103A patent/AU2017304103A1/en not_active Abandoned
-
2019
- 2019-01-29 IL IL264537A patent/IL264537A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3031895A1 (en) | 2018-02-01 |
| JP2019532021A (ja) | 2019-11-07 |
| BR112019001217A2 (pt) | 2019-04-30 |
| IL264537A (en) | 2019-02-28 |
| KR20190032534A (ko) | 2019-03-27 |
| EP3491005A1 (en) | 2019-06-05 |
| CN109563136A (zh) | 2019-04-02 |
| SG11201811412XA (en) | 2019-02-27 |
| MA45770A (fr) | 2019-06-05 |
| WO2018020358A1 (en) | 2018-02-01 |
| AU2017304103A1 (en) | 2019-01-17 |
| US20190270778A1 (en) | 2019-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018501068A1 (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| MX2021002978A (es) | Lactamas biciclicas y metodos de uso de las mismas. | |
| NZ747259A (en) | Soluble c5ar antagonists | |
| NZ768368A (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| PH12019500188A1 (en) | Piperidine cxcr7 receptor modulators | |
| MX2020006459A (es) | Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar. | |
| ZA201907746B (en) | 6-5 fused rings as c5a inhibitors | |
| PH12014502540A1 (en) | Benzimidazole-proline derivatives | |
| PH12016501310A1 (en) | Pharmaceutical compositions comprising azd9291 | |
| MX2019014292A (es) | Anillos 5-5 fusionados como inhibidores c5a. | |
| MX389592B (es) | Moduladores alostericos positivos del receptor m1 muscarinico | |
| PH12016501624A1 (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists | |
| EA201790949A1 (ru) | Замещенные 2,4-диаминохинолины в качестве новых противораковых средств | |
| PH12017501876A1 (en) | Pyridopyrimidones and their use as nmda receptor modulators | |
| PH12020550125A1 (en) | Crystalline forms of 3-substituted 1,2,4-oxadiazole | |
| JOP20190049A1 (ar) | مثبطات دوبامين-b-هيدروكسيلاز | |
| UA117154C2 (uk) | Антагоністи s1p3 | |
| ZA202001295B (en) | Thiazolopyridine derivatives as adenosine receptor antagonists | |
| MX2019001153A (es) | Peptidos ciclicos como antagonistas del receptor c5a. | |
| EA201892529A1 (ru) | Комбинация чистых антагонистов 5-htрецепторов с ингибиторами ацетилхолинэстеразы | |
| MY189372A (en) | Indole derivatives | |
| PH12018500505A1 (en) | Crystalline forms | |
| MY190027A (en) | P38 map kinase inhibiting indanyl urea compounds | |
| EA202090397A1 (ru) | Фторопиперидиновые соединения в качестве чистых антагонистов 5-ht-рецептора | |
| PH12019502792A1 (en) | Tetrahydropyridopyrazine modulators of gpr6 |